B
Bull
Bull · 25%PTHL
$24.92
情景价格
$0.902
+0.949 (+105.16%)收盘时
Loading chart…
- High
- 1.090
- Open
- 0.423
- VWAP
- 0.79
- Vol
- 74.89M
- Mkt Cap
- —
- Low
- 0.391
- Amount
- 59.49M
- EV/EBITDA, TTM
- 0.00
iTonic Holdings Ltd, formerly Pheton Holdings Ltd, is a holding company principally engaged in the provision of healthcare solutions through its subsidiary Beijing Feitian Zhaoye Technology Co., Ltd. (Beijing Feitian). The Company’s main businesses include development and commercialization of brachytherapy treatment planning system (TPS) specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. TPS is generally a computer software used in different types of radiotherapy. The Company’s main product is FTTPS, a user-oriented TPS for treating a wide variety of malignant tumors. Beijing Feitian’s product portfolio also includes Medical Auxiliary Supplies such as seed implant needles, computer workstations, patient positioning device and others.
估值指标
The current forward P/E ratio for Pheton Holdings Ltd (PTHL) is 0.00, compared to its 5-year average forward P/E of 0.00.
Alphio AI Price Scenarios for PTHL
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
事件时间线
资讯
2.008-14PRnewswireiTonic Holdings Faces Class Action Over Market Manipulation Allegations
7.008-11PRnewswirePheton Holdings Securities Class Action Reminder
7.008-07PRnewswireiTonic Holdings Sued for Market Manipulation Allegations
8.512-05GlobenewswirePheton Acquires 51% of iTonic, Expanding into Home Health Market
8.512-05NewsfilterPheton Acquires 51% of iTonic, Expanding into Home Health Market
PTHL FAQ — answered by Alphio AI
iTonic Holdings Ltd, formerly Pheton Holdings Ltd, is a holding company principally engaged in the provision of healthcare solutions through its subsidiary Beijing Feitian Zhaoye Technology Co., Ltd. (Beijing Feitian). The Company’s main businesses include development and commercialization of brachytherapy treatment planning system (TPS) specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. TPS is generally a computer software used in different types of radiotherapy. The Company’s main product is FTTPS, a user-oriented TPS for treating a wide variety of malignant tumors. Beijing Feitian’s product portfolio also includes Medical Auxiliary Supplies such as seed implant needles, computer workstations, patient positioning device and others. It operates in the Healthcare sector.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。